Top

Cancer Chemotherapy and Pharmacology

Published in:

01-09-2014 | Original Article

Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice

Authors: Memy H. Hassan, Hesham A. El-Beshbishy, Hamdy Aly, Sabry M. Attia, Saleh A. Bahashwan, Mohamed M. Ghobara

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2014

Abstract

Purpose

This study was undertaken to assess the possible modulatory effects and mechanisms of meloxicam, a cyclooxygenase-2 inhibitor, on the antitumor activity and cardiotoxicity of doxorubicin in a mice model of mammary carcinoma.

Methods

Solid tumor mass was developed in female albino mice using Ehrlich carcinoma cells. Forty mice-bearing tumor were divided randomly into four groups for treatment: with saline, meloxicam 10 mg/kg, doxorubicin 5 mg/kg and meloxicam 1 h ahead of doxorubicin, twice weekly for 2 weeks. Tumor volume was followed up and cardiac protective utility was estimated via measuring heart and serum parameters.

Results

Meloxicam expressed a non-significant increase in doxorubicin antitumor activity. Conversely, meloxicam significantly (p < 0.01) mitigated doxorubicin-induced elevation of serum cardiac enzymes [creatine kinase, lactate dehydrogenase and troponin-I]; cardiac lipid peroxidations marker; cardiac active caspase-3 content; and cardiac prostaglandin E2 content. Meloxicam significantly abrogated doxorubicin-induced disturbance in heart histology and relative heart weight to body weight. Meloxicam normalized doxorubicin-induced suppression in heart antioxidant enzymes activities and gene expressions [superoxide dismutase, glutathione peroxidase (GSH-Px) and catalase], and heart GSH content. In addition, meloxicam ameliorated doxorubicin-induced disturbance in phase II metabolizing enzyme, cardiac quinone reductase (QR), at activity level and mRNA expression.

Conclusion

Meloxicam protects heart against doxorubicin toxicity without affecting its antitumor activity against solid mammary cancer model in mice. This protective effect is attributed to antioxidant effect, antiradical effect, antiinflammatory action, antiapoptotic effect and induction of QR enzyme.

Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C (1969) Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 11:1101–1110PubMedCrossRef

Kufe DW, Holland JF, Frei E (2003) American cancer society: cancer medicine 6. BC Decker, Hamilton

Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727–741PubMedCrossRef

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229PubMedCrossRef

Sinha BK, Trush MA, Kennedy KA, Mimnaugh EG (1984) Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res 44:2892–2896PubMed

Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, Animati F (2001) Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 1:113–130PubMedCrossRef

Muindi JR, Sinha BK, Gianni L, Myers CE (1984) Hydroxyl radical production and DNA damage induced by anthracycline- iron complex. FEBS Lett 172:226–230PubMedCrossRef

Badary OA, Awad AS, Abdel-Maksoud S, Hamada FM (200) Cardiac DT-diaphorase contributes to the detoxification system against doxorubicin-induced positive inotropic effects in guinea-pig isolated atria. Clin Exp Pharmacol Physiol 31(12):856–861

Gutierrez PL (2000) The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: a review. Free Radic Biol Med 3–4:263–275CrossRef

10.

Osman AM, Al-Harthi SE, Alarabi OM, Elshal MF, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA, Osman OH (2013) Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int 13(1):52PubMedCentralPubMedCrossRef

11.

Adderley S, Fitzgerald D (1999) Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase 2. J Biol Chem 27:5038–5046CrossRef

12.

Wolfesberger B, Walter I, Hoelzl C, Thalhammer JG, Egerbacher M (2006) Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res Vet Sci 80(3):308–316PubMedCrossRef

13.

Mizutani Y, Kamoi K, Ukimura O, Kawauchi A, Miki T (2002) Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. J Urol 168(6):2650–2654PubMedCrossRef

14.

Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59:198–204PubMed

15.

Arun B, Goss P (2004) The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31:22–29PubMedCrossRef

16.

Zatelli MC, Molè D, Tagliati F, Minoia M, Ambrosio MR, degli Uberti E (2009) Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB. Cell Oncol 31(6):457–465PubMed

17.

Han HK, Choi HK (2007) Improved absorption of meloxicam via salt formation with ethanolamines. Eur J Pharm Biopharm 65:99–103PubMedCrossRef

18.

Gates BJ, Nguyen TT, Setter SM, Davies NM (2005) Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother 6:2117–2140PubMedCrossRef

19.

Kalonia H, Kumar A (2011) Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington’s disease-like alterations in rats. Life Sci 88:784–791PubMedCrossRef

20.

Edfawy M, Hassan MH, Mansour A, Hamed AA, Amin HA (2012) Meloxicam modulates oxidative stress status, inhibits prostaglandin E2, and abrogates apoptosis in carbon tetrachloride-induced rat hepatic injury. Int J Toxicol 31(3):276–286PubMedCrossRef

21.

Yamamoto D, Iwase S, Yoshida H, Kuroda Y, Yamamoto C, Kitamura K, Odagiri H, Nagumo Y (2011) Efficacy of meloxicam in combination with preoperative chemotherapy for breast cancer—Japan Breast Cancer Research Network (JBCRN) 02-1 trial. Anticancer Res 31(10):3567–3571PubMed

22.

Naruse T, Nishida Y, Ishiguro N (2007) Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells. Biomed Pharmacother 61(6):338–346PubMedCrossRef

23.

Osman A, Sayed-Ahmed M, Khayyal M, El Merzebani M (1993) Hyperthermic potentiation of cisplatin on solid Ehrlich carcinoma. Tumouri 79:268–272

24.

Azab SS, Salama SA, Hassan MH, Khalifa AE, El-Demerdash E, Fouad H, Al-Hendy A, Abdel-Naim AB (2008) 2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft. Cancer Chemother Pharmacol 62(5):893–902PubMedCrossRef

25.

Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM (2004) Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 6(4):R275–R283PubMedCentralPubMedCrossRef

26.

Bancroft J, Stevens A (1996) Enzyme histochemistry: theory and practice of histological techniques. Churchill Livingstone, New York

27.

Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRef

28.

Moron MS, Depierre JW, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 582(1):67–78PubMedCrossRef

29.

Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:469–474PubMedCrossRef

30.

Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70(1):158–169PubMed

31.

Sinha AK (1972) Colorimetric assay of catalase. Anal Biochem 47:389–394PubMedCrossRef

32.

Benson AM, Hunkeler MJ, Talalay P (1980) Increase of NADPH, quinone reductase activity by dietary antioxidant: possible role in protection against carcinogenesis and toxicity. Proc Nat Aca Sci USA 77:5216–5220CrossRef

33.

Pfaffl MW (2001) A new mathematical model for relative quantifications in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCentralPubMedCrossRef

34.

Al-Hendy A, Lee EJ, Wang HQ, Copland JA (2004) Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 191:1621–1631PubMedCrossRef

35.

Al-Shabanah OA, Osman AM, Al-Harbi MM, Al-Gharably NM, Al-bekairi AM, El-Merzabani MM (1996) Effect of hyperthermia on the action of methotrexate against the growth of Ehrlich ascites carcinoma cells. Med Sci Res 24:275–277

36.

Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) Clinic opathologic analysis of adriamycin cardiotoxicity. Cancer 32:302–314PubMedCrossRef

37.

Osman AM, Nemnem MM, Abou-Bakr AA, Nassier OA, Khayyal MT (2009) Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice. Food Chem Toxicol 47(10):2425–2430PubMedCrossRef

38.

Das J, Ghosh J, Manna P, Sil PC (2011) Taurine suppresses doxorubicin-triggered oxidative stress and cardiac apoptosis in rat via up-regulation of PI3-K/Akt and inhibition of p53, p38-JNK. Biochem Pharmacol 81(7):891–909PubMedCrossRef

39.

Cummings J, Allan L, Willmott N, Riley R, Workman P, Smyth JF (1992) The enzymology of doxorubicin quinone reduction in tumour tissue. Biochem Pharmacol 44:2175–2183PubMedCrossRef

40.

Lind C, Hoshstein P, Ernster L (1982) DT-Diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys 216:178–185PubMedCrossRef

41.

Iqbal M, Okada S (2003) Induction of NAD(P)H:quinone reductase by probucol: a possible mechanism for protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 93(6):259–263PubMedCrossRef

42.

Kolesar JM, Kuhn JG, Burris HA III (1995) Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. J Natl Cancer Inst 87:1022–1024PubMedCrossRef

43.

Powis G, Gasdaska PY, Gallegos A, Sherrill K, Goodman D (1995) Overexpression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs. Anticancer Res 15:1141–1145PubMed

44.

Wang X, Doherty GP, Leith MK, Curphey TJ, Begleiter A (1999) Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer 80:1223–1230PubMedCentralPubMedCrossRef

45.

Liu TJ, Yeh YC, Ting CT, Lee WL, Wang LC, Lee HW, Wang KY, Lai HC, Lai HC (2008) Ginkgo biloba extract 761 reduces doxorubicin-induced apoptotic damage in rat hearts and neonatal cardiomyocytes. Cardiovasc Res 80:227–235PubMedCrossRef

46.

Arantes-Rodrigues R, Pinto-Leite R, Ferreira R, Neuparth MJ, Pires MJ, Gaivão I, Palmeira C, Santos L, Colaço A, Oliveira P (2013) Meloxicam in the treatment of in vitro and in vivo models of urinary bladder cancer. Biomed Pharmacother 67(4):277–284PubMedCrossRef

Title: Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice
Authors: Memy H. Hassan
Hesham A. El-Beshbishy
Hamdy Aly
Sabry M. Attia
Saleh A. Bahashwan
Mohamed M. Ghobara
Publication date: 01-09-2014
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2544-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2014

Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer

Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients

Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404

A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer